Fiori Cristian, De Cillis Sabrina, Volpi Gabriele, Checcucci Enrico, Cattaneo Giovanni, Meziere Juliette, Manfredi Matteo, Dio Michele Di, Amparore Daniele, Porpiglia Francesco
Division of Urology, Department of Oncology, University of Turin School of Medicine, San Luigi Hospital, Orbassano, Italy.
Division of Urology, Department of Surgery, Annunziata Hospital, Cosenza, Italy.
Turk J Urol. 2021 Nov;47(6):470-481. doi: 10.5152/tud.2021.21145.
In the last few years, new technologies have been developed to treat benign prostatic hyperplasia (BPH) in order to offer valid surgical alternatives to transurethral resection of the prostate with lower complications and hospitalization while maintaining satisfactory functional results. Among these new approaches, transurethral implantation of first- and second-generation temporary implantable nitinol device (TIND and iTIND, respectively) (Medi-TateVR ; Medi-Tate Ltd., Or Akiva, Israel) has been proposed. The aim of this work is to describe the surgical technique and to perform a systematic review of the available literature on follow-up of functional outcomes. A systematic research of the available literature on this topic was performed via Medline, Embase, and Cochrane databases in April 2021. Current evidence regarding the implantation of iTIND to treat BPH-related lower urinary tract symptoms (LUTSs) is still limited. Seven studies have been found. Only one randomized controlled trial has been published reporting short-term follow-up of implantation of iTIND versus sham procedure. All the studies reported that both procedures are safe, effective, and well-tolerated. Moreover, such treatment seems to not affect patient's sexual and ejaculatory functions. In conclusions, current clinical evidence suggests that temporary implantation of iTIND is a valid option for the minimally invasive surgical treatment of BPH-related LUTS. Further studies are required in order to confirm the functional results, especially over a long-term follow-up.
在过去几年中，已开发出新技术来治疗良性前列腺增生（BPH），以便在维持令人满意的功能结果的同时，提供有效的手术替代方案，以降低经尿道前列腺切除术的并发症和住院率。在这些新方法中，已有人提出经尿道植入第一代和第二代临时可植入镍钛诺装置（分别为TIND和iTIND）（Medi-TateVR；Medi-Tate有限公司，以色列奥阿基瓦）。这项工作的目的是描述手术技术，并对有关功能结果随访的现有文献进行系统综述。2021年4月，通过Medline、Embase和Cochrane数据库对该主题的现有文献进行了系统检索。关于植入iTIND治疗BPH相关下尿路症状（LUTS）的现有证据仍然有限。共找到七项研究。仅发表了一项随机对照试验，报告了iTIND植入与假手术的短期随访情况。所有研究均报告这两种手术都是安全、有效的，且耐受性良好。此外，这种治疗似乎不会影响患者的性功能和射精功能。总之，目前的临床证据表明，临时植入iTIND是微创治疗BPH相关LUTS的有效选择。需要进一步研究以确认功能结果，尤其是长期随访结果。
